Literature DB >> 16567837

The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program.

Mercedes R Carnethon1, Ronald J Prineas, Marinella Temprosa, Zhu-Ming Zhang, Gabriel Uwaifo, Mark E Molitch.   

Abstract

OBJECTIVE: Autonomic nervous system dysfunction, a correlate of obesity and poor cardiorespiratory fitness, is associated with the development of diabetes. We tested whether estimates of autonomic nervous system function improved in the intensive lifestyle versus metformin or placebo arms of the Diabetes Prevention Program (DPP) and whether baseline or a change in autonomic nervous system function was associated with the development of diabetes over 3.2 years. RESEARCH DESIGN AND METHODS: In 2,980 DPP participants, 12-lead electrocardiograms were measured at baseline and annually. Heart rate, heart rate variability (HRV), and QT duration were used to estimate fitness and autonomic nervous system function.
RESULTS: In the lifestyle arm, heart rate and QT indexes decreased, and HRV increased over time. The magnitude of decline in heart rate and QT duration was substantially smaller in the other arms, whereas HRV did not increase. Baseline heart rate was the only index significantly (P < 0.05) associated with incident diabetes after adjustment for demographics and weight change (hazard ratio for lifestyle and metformin arms = 1.19 and 1.17 per 10.6 beats/min, respectively). Decreases in heart rate and QT indexes and increases in HRV over time were associated with a lower risk of developing diabetes. The protective association between decreased heart rate and incident diabetes in the lifestyle arm remained significant after accounting for change in weight and physical activity.
CONCLUSIONS: Indexes that reflect autonomic function and fitness improved (i.e., heart rate decreased and HRV increased) in the lifestyle modification arm of the DPP. Improvements in these indexes are inversely associated with the development of diabetes independent of weight change.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16567837      PMCID: PMC1751934          DOI: 10.2337/diacare.29.04.06.dc05-1729

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  33 in total

1.  Methodology of ECG interpretation in the Dalhousie program; NOVACODE ECG classification procedures for clinical trials and population health surveys.

Authors:  P M Rautaharju; P J MacInnis; J W Warren; H K Wolf; P M Rykers; H P Calhoun
Journal:  Methods Inf Med       Date:  1990-09       Impact factor: 2.176

2.  NOVACODE serial ECG classification system for clinical trials and epidemiologic studies.

Authors:  P M Rautaharju; H P Calhoun; B R Chaitman
Journal:  J Electrocardiol       Date:  1992       Impact factor: 1.438

3.  Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.

Authors: 
Journal:  Diabetes Care       Date:  1997-07       Impact factor: 19.112

4.  Heart rate variability at rest and exercise: influence of age, gender, and physical training.

Authors:  J Gregoire; S Tuck; Y Yamamoto; R L Hughson
Journal:  Can J Appl Physiol       Date:  1996-12

5.  QTc duration is associated with levels of insulin and glucose intolerance. The Zutphen Elderly Study.

Authors:  J M Dekker; E J Feskens; E G Schouten; P Klootwijk; J Pool; D Kromhout
Journal:  Diabetes       Date:  1996-03       Impact factor: 9.461

6.  Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.

Authors: 
Journal:  Circulation       Date:  1996-03-01       Impact factor: 29.690

7.  Association of vagal tone with serum insulin, glucose, and diabetes mellitus--The ARIC Study.

Authors:  D Liao; J Cai; F L Brancati; A Folsom; R W Barnes; H A Tyroler; G Heiss
Journal:  Diabetes Res Clin Pract       Date:  1995-12       Impact factor: 5.602

8.  Effect of metabolic control on autonomic function in obese patients with newly diagnosed type 2 diabetes.

Authors:  E Vanninen; M Uusitupa; E Länsimies; O Siitonen; J Laitinen
Journal:  Diabet Med       Date:  1993 Jan-Feb       Impact factor: 4.359

9.  Autonomic neural dysfunction in recently diagnosed diabetic subjects.

Authors:  M A Pfeifer; C R Weinberg; D L Cook; A Reenan; J B Halter; J W Ensinck; D Porte
Journal:  Diabetes Care       Date:  1984 Sep-Oct       Impact factor: 19.112

10.  Insulin-mediated glucose metabolism in the relationship between dietary intake and sympathetic nervous system activity.

Authors:  L Landsberg; J B Young
Journal:  Int J Obes       Date:  1985
View more
  72 in total

Review 1.  Diabetic Polyneuropathy - Advances in Diagnosis and Intervention Strategies.

Authors:  Solomon Tesfaye; Gordon Sloan
Journal:  Eur Endocrinol       Date:  2020-04-17

Review 2.  What do we know and we do not know about cardiovascular autonomic neuropathy in diabetes.

Authors:  Rodica Pop-Busui
Journal:  J Cardiovasc Transl Res       Date:  2012-05-30       Impact factor: 4.132

3.  Reference ranges for short-term heart rate variability measures in individuals free of cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Wesley T O'Neal; Lin Y Chen; Saman Nazarian; Elsayed Z Soliman
Journal:  J Electrocardiol       Date:  2016-06-29       Impact factor: 1.438

4.  Increased prevalence of cardiac autonomic dysfunction at different degrees of glucose intolerance in the general population: the KORA S4 survey.

Authors:  Dan Ziegler; Andreas Voss; Wolfgang Rathmann; Alexander Strom; Siegfried Perz; Michael Roden; Annette Peters; Christa Meisinger
Journal:  Diabetologia       Date:  2015-02-28       Impact factor: 10.122

Review 5.  Neuropathy in prediabetes: does the clock start ticking early?

Authors:  Nikolaos Papanas; Aaron I Vinik; Dan Ziegler
Journal:  Nat Rev Endocrinol       Date:  2011-07-12       Impact factor: 43.330

6.  Heart rate recovery after exercise and incidence of type 2 diabetes in men.

Authors:  Sae Young Jae; Mercedes R Carnethon; Kevin S Heffernan; Bo Fernhall; Moon-Kyu Lee; Won Hah Park
Journal:  Clin Auton Res       Date:  2009-04-16       Impact factor: 4.435

Review 7.  The prevention of type 2 diabetes.

Authors:  Jill P Crandall; William C Knowler; Steven E Kahn; David Marrero; Jose C Florez; George A Bray; Steven M Haffner; Mary Hoskin; David M Nathan
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2008-05-20

8.  Galantamine alleviates inflammation and insulin resistance in patients with metabolic syndrome in a randomized trial.

Authors:  Fernanda M Consolim-Colombo; Carine T Sangaleti; Fernando O Costa; Tercio L Morais; Heno F Lopes; Josiane M Motta; Maria C Irigoyen; Luiz A Bortoloto; Carlos Eduardo Rochitte; Yael Tobi Harris; Sanjaya K Satapathy; Peder S Olofsson; Meredith Akerman; Sangeeta S Chavan; Meggan MacKay; Douglas P Barnaby; Martin L Lesser; Jesse Roth; Kevin J Tracey; Valentin A Pavlov
Journal:  JCI Insight       Date:  2017-07-20

9.  Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter.

Authors:  P Valensi; S Chiheb; M Fysekidis
Journal:  Diabetologia       Date:  2013-04-13       Impact factor: 10.122

10.  A twin study of metabolic syndrome and autonomic tone.

Authors:  Anil K Gehi; Rachel Lampert; Emir Veledar; Forrester Lee; Jack Goldberg; Linda Jones; Nancy Murrah; Ali Ashraf; Viola Vaccarino
Journal:  J Cardiovasc Electrophysiol       Date:  2008-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.